May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Encouraging Activity Shown With Neoadjuvant Enfortumab Vedotin in Muscle Invasive Bladder Cancer
February 19th 2022Patients with muscle invasive bladder cancer ineligible for cisplatin in cohort H of the phase 1b/2 EV-103 trial demonstrated promising antitumor activity when receiving neoadjuvant enfortumab vedotin.
Read More
Sacituzumab Govitecan With Pembrolizumab Demostrates Encrouaging Anti-Tumor Activity in mUC
February 19th 2022Patients with checkpoint inhibitor–naïve metastatic urothelial cancer had promising anti-tumor activity when treated with sacituzumab govitecan and pembrolizumab in the second-line setting.
Read More
Upfront Avelumab Maintenance Demonstrates Continued OS Benefit in Advanced UC
February 18th 2022An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Read More
Gene Therapy Shows Encouraging Clinical Efficacy/Safety in BCG-Unresponsive NMIBC
February 11th 2022A novel gene therapy is being investigated for the treatment of Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, and the preliminary findings signal a high response rate with little toxicity.
Read More
Disease Recurrence Not Significantly Delayed With Panvac Plus BCG in Advanced NMIBC
September 13th 2021n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.
Read More
Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 13th 2021Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.
Read More
Aveluamab With BCG Induction Shows Early Safety/Tolerability in BCG-Unresponsive NMIBC
September 13th 2021Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Read More